GLYC - GlycoMimetics Can Become A Game Changer In Blood Cancers
2024-03-21 17:47:38 ET
Summary
- GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
- AML is a disease with a poor prognosis, especially for elderly patients, and there is a need for better treatment options.
- Uproleselan, a glycomimetic drug, aims to achieve minimal residual disease negativity and improve long-term survival outcomes in AML patients.
Written by Dan Cohen and Scott Matusow
- Introduction and primer on GlycomiMetics ( GLYC )
After almost 6 years in pivotal studies, GlycomiMetics' Uproleselan is finally slated to read out data in both relapsed/refractory (r/r) and elderly newly diagnosed Acute Myeloid Leukemia (AML). The small-cap company has certainly taken an unusual route for its size by utilizing study designs with a rather long time to analysis. However, by doing so, they may be able to establish a definitive dataset that can fundamentally change the way hematologists approach this debilitating disease....
GlycoMimetics Can Become A Game Changer In Blood Cancers